Inspire (INSP) Q3 2026 Earnings Call Transcript

Inspire Medical Systems reported Q3 2026 revenue of $206.7 million, down 7.9% year over year but up 3% sequentially; adjusted diluted EPS fell to $0.14 from $0.37. Management estimated coding and reimbursement challenges reduced Q3 results by about $30 million and put the full-year 2026 headwind at approximately $120 million, while narrowing revenue guidance to $850 million–$860 million. The company expects low single-digit revenue growth in 2027, citing a more stable coding environment, Project Horizon investments and battery replacements; a new Category I CPT code for Inspire V is scheduled to take effect Jan. 1, 2028.

Analysis

The key risk is that investors treat the 2026 reimbursement drag as deferred demand that automatically returns in 2027. Management’s low-single-digit growth outlook despite easier comparisons suggests some patients may be delayed, lost from the funnel, or constrained by clinic capacity—not simply waiting for cleaner codes. The upcoming OPPS final rule is therefore a near-term catalyst, but a favorable facility rate alone may not restore procedure volumes if sites remain cautious or the physician-fee valuation disappoints. The RUC process creates a separate, longer-dated risk: a more efficient procedure could support ASC adoption while also weakening the case for professional reimbursement if time and support costs are undervalued.

Project Horizon’s $30 million is investment capacity, not evidence of incremental profit; the payoff depends on whether added field support and patient-navigation spending convert into implants. Watch patient-flow conversion and center utilization, not just hiring or marketing activity. Battery replacements could add a steadier revenue layer, but management’s own framing implies they are not yet large enough to underwrite a growth re-rating. Cardiovascular-channel expansion is a longer-term option, not near-term proof of an expanded addressable market: the cited association with better outcomes versus CPAP is observational, and referral behavior must still change. GLP-1s are two-sided: weight loss may remove some OSA patients from the pool while making others eligible for Inspire.

The contrarian risk is upside if coding clarity releases genuinely deferred demand and ASCs expand access faster than the cautious 2027 outlook implies. Conversely, a positive CMS rule without improving conversion would expose the gap between reimbursement normalization and actual demand. No valuation or share-price data are provided, so sizing should remain event- and confirmation-driven.

Key Decisions for Investors

• Keep INSP underweight ahead of the final 2027 OPPS rule; do not treat the expected Q4 seasonal step-up as evidence that underlying growth has repaired. Reassess after the rule and Q4 results.
• If the final OPPS rule materially disappoints versus the proposed increase, or management signals persistent site-level billing friction, consider a defined-risk 1–3 month INSP put spread after the announcement rather than taking uncapped event risk beforehand. Thesis is falsified by a broadly supportive final rule followed by improving procedure conversion and a raised 2027 outlook.
• If reimbursement is supportive, wait for operating confirmation before adding: monitor new-center activation, utilization at existing centers, ASC mix, and whether deferred patients convert. Failure to improve these measures despite coding clarity would argue that the $120 million headwind was not predominantly recoverable demand.